uploads/2018/03/Oncology-2.png

Update on Eli Lilly’s Oncology Drugs Erbitux, Gemzar, Lartruvo

By

Updated

Erbitux’s revenue trends

In 4Q17, Eli Lilly’s (LLY) Erbitux reported revenues of $168.9 million, which reflected a ~10% growth on a YoY (year-over-year) basis and a ~3% growth quarter-over-quarter.

In 2017, Erbitux generated revenues of $645.9 million compared to $687 million in 2016. In 2017, in the US market and international markets, Erbitux reported revenues of $541.7 million and $104.2 million, respectively, compared to $581.1 million and $105.9 million, respectively, in 2016.

Article continues below advertisement

Gemzar’s revenue trends

In 4Q17, Gemzar generated revenues of $30.4 million, which reflected a ~41% growth on a YoY basis and a ~13% growth on a quarter-over-quarter basis.

In 4Q17, in the US market and international markets, Gemzar reported revenues of $2.9 million and $27.5 million, respectively.

In fiscal 2017, Gemzar generated revenues of $110.9 million compared to $111.0 million in 2016.

In the marketplace, Gemzar’s competitor drug is Celgene’s (CELG) Abraxane.

Lartruvo’s revenue trends

In 4Q17, Lartruvo generated revenues of $59 million compared to $11.9 million in 4Q16. In 4Q17, Lartruvo witnessed an ~8% growth on a quarter-over-quarter basis.

In 4Q17, in the US market and international markets, Lartruvo generated revenues of $41.5 million and $17.5 million, respectively.

In fiscal 2017, Lartruvo reported revenues of $203 million, including revenues of $161.7 million and $41.2 million from the US market and international markets, respectively, compared to $11.4 million and $0.5 million in 2016.

Revenue trends for Portrazza and Verzenio

In 4Q17, Portrazza generated revenues of $2.1 million, which included $1.9 million and $0.2 million from the US and international markets, respectively. In fiscal 2017, Portrazza generated revenues of $10.3 million, including $9.3 million and $1 million from the US market and international markets, respectively.

In 4Q17, Verzenio generated revenues of $21 million. In September 2017, the FDA approved Verzenio for the treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy.

In the marketplace, Verzenio competes with Roche’s (RHHBY) Herceptin and Perjeta and Novartis’s (NVS) Tykerb.

Advertisement

More From Market Realist